Aethlon shows Hemopurifier safety, strong EV removal but warns of going-concern

Aethlon Medical, Inc. (NASDAQ: AEMD) - Quick read

Summary:
- Clinical-stage medical device developer focused on the Hemopurifier®; FDA Breakthrough Device designation for two indications.
- Showing early safety signals in Phase 1 oncology (Australia) but no commercial revenue - still burning cash and facing a going-concern warning.

Key financials (quarter ended June 30, 2025)
- Cash and cash equivalents: $3,765,154 (June 30, 2025) - down from $5,501,261 (Mar 31, 2025).
- Cash, cash equivalents and restricted cash: $3,863,284 (June 30, 2025).
- Working capital: $2,423,421 (June 30, 2025).
- Total assets: $5,306,002; Total liabilities: $1,882,489; Stockholders' equity: $3,423,513 (June 30, 2025).
- Net loss (three months): $(1,761,858) vs $(2,571,440) year-ago.
- Operating expenses: $1,792,390 vs $2,620,858 year-ago (down 31.6%).
- R&D (disclosed internal measure): $524,000 (Q) vs $415,000 (prior Q).
- Net cash used in operating activities: $(1,714,937) for the quarter.
- Basic & diluted loss per share: $(0.85); weighted average shares: 2,076,416 (vs $(2.76) on 932,248 prior year).
- Shares outstanding (reported Aug 13, 2025): 2,598,711.
- Warrants outstanding: 2,129,187 (weighted avg exercise ~$3.44).
- Unrecognized stock-based comp: ~$206,106 remaining (to be recognized over ~0.71 years).

What's happening inside the company
- Clinical progress: Phase 1 oncology trial open at three Australian sites; three participants treated in Cohort 1 (single 4‑hour treatment). DSMB reviewed Cohort 1 and reported no safety concerns; Cohort 2 enrollment open (two treatments over one week).
- India program: CDSCO approval was obtained but the company cancelled plans for the India trial after CRO timelines extended - redirecting resources to Australia.
- Preclinical work: Ex‑vivo study reported >98% removal of platelet‑derived EVs in simulated session; manuscript submitted for peer review and published as preprint on bioRxiv.
- Manufacturing/regulatory: Inventory sufficient for current Australian trial; FDA approved manufacturing at San Diego facility under IDE supplement but company awaits FDA qualification of an additional supplier for a key component.
- Corporate actions: 1‑for‑8 reverse stock split effective June 9, 2025; RSU grants to directors (71,432 RSUs granted in Q) with 13,395 shares vested/issued during quarter.

Income statement - positive aspects
- Operating expense decline: Total operating expenses fell 31.6% YoY to $1.79M - driven largely by lower payroll (headcount reductions and no prior-year severance accrual).
- Reduced payroll expense: Payroll and related expenses down to $581,000 from $1,254,802 (Q) - lowers burn going forward if headcount reduction is sustained.
- Improved per‑share loss: Loss per share narrowed to $(0.85) from $(2.76) as share count increased and absolute loss declined.
- R&D investment maintained: R&D spend increased (internal R&D figure $524k), signaling continued clinical and preclinical progress rather than a cut to development.

Income statement - negative aspects
- No revenue: The company recognized zero revenue for the quarter - all activity is R&D and development-stage spending.
- Continued losses and cash burn: Net loss of $(1.76M) and operating cash burn ~$1.715M in the quarter - runway limited by current cash balance.
- Going-concern: Management explicitly states existing cash is not expected to fund operations for at least 12 months - substantial doubt about ability to continue as a going concern.
- Dilution risk: Significant potential dilution exists - >2.1M warrants outstanding plus unvested RSUs and options; future equity raises likely required.
- Stock-based metrics unfavorable: Outstanding options are out-of-the-money (closing price $1.20 on June 30, 2025 vs high exercise prices), and equity grants continue to add to share count and compensation expense.

Near-term catalysts and risks
- Catalysts: DSMB safety confirmation and enrollment progress in Australian Phase 1; publication/submission of preclinical EV removal data; potential FDA supplier qualification (enables scale manufacturing).
- Risks: Need for financing - absence of near-term capital could force program cuts; clinical trial enrollment pace; dependence on FDA interactions and supplier qualification; patent/ IP expiration timing; market and macro uncertainties that could impair raising capital.

Bottom line
- Aethlon Medical (NASDAQ: AEMD) is advancing its Hemopurifier program with encouraging early safety data and strong preclinical EV removal results, yet remains a pre‑revenue, development‑stage company with a narrow cash runway and a formal going‑concern disclosure. The company needs additional financing to sustain trials and manufacturing scale; watch trial enrollment, FDA supplier qualification, and any financing/dilution events as primary drivers of near-term investor outcomes.

Data sourced from Aethlon Medical, Inc. Form 10‑Q for the quarter ended June 30, 2025 (filed Aug 13, 2025).